About Saga Diagnostics
Saga Diagnostics is a company based in Lund (Sweden) founded in 2016 was acquired by Foundation Medicine in April 2026. Saga Diagnostics has raised $17.87 million across 7 funding rounds from investors including Foundation Medicine, European Union and Segulah Medical Acceleration. Saga Diagnostics offers products and services including MRD Testing Platform and Liquid Biopsy Test. Saga Diagnostics operates in a competitive market with competitors including Guardant Health, GRAIL, Foundation Medicine, ArcherDX and Natera, among others.
- Headquarter Lund, Sweden
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Saga Diagnostics Ab
-
Annual Revenue
$2.92 M (USD)434as on Dec 31, 2022
-
Net Profit
-$2.63 M (USD)0as on Dec 31, 2022
-
EBITDA
-$2.63 M (USD)0as on Dec 31, 2022
-
Total Equity Funding
$17.87 M (USD)
in 7 rounds
-
Latest Funding Round
$12.47 M (USD), Series A
Jun 29, 2021
-
Investors
Foundation Medicine
& 11 more
-
Employee Count
Not available
-
Acquired by
Foundation Medicine
(Apr 16, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Saga Diagnostics
Saga Diagnostics offers a comprehensive portfolio of products and services, including MRD Testing Platform and Liquid Biopsy Test.
Detects residual cancer cells via liquid biopsy for personalized oncology care.
Monitors tumor variants in blood to assess treatment response and recurrence.
People of Saga Diagnostics
Unlock access to complete
Funding Insights of Saga Diagnostics
Saga Diagnostics has successfully raised a total of $17.87M across 7 strategic funding rounds. The most recent funding activity was a Series A round of $12.47 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Saga Diagnostics
Saga Diagnostics has secured backing from 12 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Foundation Medicine, European Union and Segulah Medical Acceleration.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investment support is provided for life science and high tech.
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked |
Investor details for Saga Diagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Saga Diagnostics
Investment portfolio details for Saga Diagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Saga Diagnostics
Detailed financials for Saga Diagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Saga Diagnostics Comparisons
Peer comparison for Saga Diagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Saga Diagnostics
Saga Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Foundation Medicine, ArcherDX and Natera, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
Detailed competitors of Saga Diagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Saga Diagnostics
Complete news archive for Saga Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Saga Diagnostics
Saga Diagnostics was founded in 2016.
Saga Diagnostics is headquartered in Lund, Sweden.
Saga Diagnostics is a funded company, having raised a total of $17.87M across 7 funding rounds to date.
Annual revenue of Saga Diagnostics is $2.92M as on Dec 31, 2022.
Saga Diagnostics was founded in 2016 in Lund, Sweden, and operates in the biotechnology sector focused on oncology diagnostics. Next-generation sequencing and proprietary algorithms are utilized to identify cell-free tumor DNA in blood samples. Products such as SAGAsafe, SAGAsign, and SAGAseq are developed to detect mutations and assess therapeutic responses. Services for analyzing gene and chromosomal mutations are also provided to support clinical research and patient monitoring.
Saga Diagnostics's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
Saga Diagnostics offers MRD Testing Platform and Liquid Biopsy Test.
Saga Diagnostics has 12 investors. Key investors include Foundation Medicine, European Union, Segulah Medical Acceleration, Hadean Ventures, and Gunnar Nilssons Cancerstiftelse.